NEW YORK, June 28, 2017 /PRNewswire/ --
If you want a Stock Review on APRI, DRRX, SCMP or SCLN then come over tohttp://dailystocktracker.com/register/ and sign up for your free customized report today. DailyStockTracker.com shifts focus on four Drug Manufacturers stocks, namely: Apricus Biosciences Inc. (NASDAQ: APRI), DURECT Corp. (NASDAQ: DRRX), Sucampo
On Tuesday, shares in San Diego, California headquartered Apricus Biosciences Inc. recorded a trading volume of 128,247 shares. The stock ended at $1.09, up 1.87% from the last trading session. The Company's shares have gained 14.74% in the last one month. The stock is trading below its 50-day moving average by 0.59%. Furthermore, shares of Apricus Biosciences, which focuses on the development and commercialization of product candidates in the areas of urology and rheumatology, have a Relative Strength Index (RSI) of 53.50. Access our complete research report on APRI for free at:
Cupertino, California headquartered DURECT Corp.'s stock finished yesterday's session 2.67% higher at $1.54 with a total trading volume of 668,482 shares. The Company's shares have gained 20.31% in the last month, 61.37% over the previous three months, and 14.93% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 35.17% and 29.87%, respectively. Furthermore, shares of DURECT, which researches and develops medicines based on its epigenetic regulator and drug delivery programs, have an RSI of 76.21.
On June 22nd, 2017, DURECT announced that patient enrollment has been completed in PERSIST - the pivotal Phase-3 clinical trial of POSIMIR® (SABER®-Bupivacaine), an investigational locally acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery. The Company looks forward to completing patient follow-up visits during the third quarter, and announcing top-line data in Q4 of this year. The complimentary research report on DRRX can be downloaded at:
At the close of trading on Tuesday, shares in Rockville, Maryland headquartered Sucampo Pharmaceuticals Inc. saw a drop of 3.26%, ending the day at $10.40. The stock recorded a trading volume of 316,141 shares. The Company's shares have advanced 1.46% in the last one month. The stock is trading 2.36% above its 50-day moving average. Moreover, shares of Sucampo Pharma, which focuses on developing, identifying, acquiring, and marketing medicines that meet unmet medical needs, primarily in gastroenterology, ophthalmology, and oncology-related disorders in the US, Japan, Switzerland, and internationally, have an RSI of 53.94.
On June 13th, 2017, Sucampo Pharmaceuticals announced that the US Patent and Trademark Office has issued a patent for VTS-270, a novel and well characterized 2-hydroxypropyl-beta-cyclodextrin (HP?CD) product, under investigation as an intrathecally administered treatment for Niemann-Pick Disease Type C1. The patent, U.S. Patent No. 9,675,634, relates to proprietary cyclodextrin compositions with a specific fingerprint and purity profile that distinguish VTS-270 from other HP?CD products. It expires in 2036. Register for free on DailyStockTracker.com and get access to the latest report on SCMP at:
Foster City, California headquartered SciClone Pharmaceuticals Inc.'s shares ended the day 0.46% lower at $10.90 with a total trading volume of 266,289 shares. The stock has gained 16.58% in the last month, 11.22% over the previous three months, and 0.93% on an YTD basis. The Company's shares are trading 9.26% above their 50-day moving average and 8.92% above their 200-day moving average. Additionally, shares of SciClone Pharma, which provides therapies for oncology, infectious diseases, and cardiovascular disorders in the People's Republic of China, the US, and Hong Kong, have an RSI of 66.40.
On June 08th, 2017, SciClone Pharma and a consortium consisting of entities affiliated with GL Capital Management GP Limited, Bank of China Group Investment Limited, CDH Investments, Ascendent Capital Partners, and Boying (collectively, the "Buyer Consortium") announced that they have entered into a definitive merger agreement under which the latter will acquire all the outstanding shares of SciClone for $11.18 per share in cash. The transaction will be funded by the Buyer Consortium through a combination of equity financing and debt financing.
On June 08th, 2017, research firm Maxim Group downgraded the Company's stock rating from 'Buy' to 'Hold'. Download your free research report on SCLN at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: (207) 331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Adult immunization is needed for adults whose mandatory childhood vaccines were either missed out ...
Snake antivenom is a medicine used for the treatment of patients suffering from snake envenomation.
Breast Cancer Risk Assessment Calculator predicts the risk for breast cancer. Find list of breast ...View All